Tango Therapeutics Inc. (TNGX), a clinical-stage biotechnology company, is scheduled to present at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 7, 2025.
The company is focused on developing the next generation of precision medicine for cancer treatment. Its clinical pipeline includes oral PRMT5 inhibitors TNG462 and TNG456, as well as TNG260, an oral CoREST inhibitor.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com